OMVs have also been shown to retain their biological functions in vivo after oral administration
PMCID: PMC3874122.10.1159/000353569 [PMC free article: PMC3874122] [PubMed: 23941761] [CrossRef] 347
Renal effects of drugs that inhibit prostaglandin synthesis
Translational andrology and urology , 7 (Suppl 3), p.S348
In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation
When you're ready to ensure your research is built on a foundation of quality, we're here to help you Get Started Today